Dalbavancin (Biosearch Italia/Versicor).

Biosearch Italia and Versicor are developing dalbavancin, a novel semisynthetic derivative of the natural glycopeptide A-40926 for the potential treatment of Gram-positive infections. In May 2001, the compound entered phase II trials in the US [409929], [409932]. As of Janaury 2002, phase II trials in skin infections and bacteremia were ongoing [436430]. Both dalbavancin and MDL-63246 are dimethylaminopropyl amide derivatives of A-40926; dalbavancin differs from MDL-63246 in its acylamino sugar, which consists of glucuronic acid in dalbavancin and glucosamine in MDL-63246 [216093], [298527]. The development of MDL-63246 has been discontinued [298527]. In January 1999, Versicor gained North American market rights to BI-397 [311500]. In January 2002, UBS Warburg predicted filing of an NDA in the second half of 2003 for dalbavancin, for treatment of complicated skin and soft tissue infections [439472]. In December 2001, Lehman Brothers predicted a late 2005 launch for dalbavancin, with sales of US $7.7 million in 2005, US $65.8 million in 2006, and peak sales of US $225 million in 2008 [439469].
AuthorsMatthias Steiert, Franz-Josef Schmitz
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 3 Issue 2 Pg. 229-33 (Feb 2002) ISSN: 1472-4472 [Print] England
PMID12020051 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Infective Agents
  • Drugs, Investigational
  • Glycopeptides
  • Teicoplanin
  • dalbavancin
  • Anti-Infective Agents (pharmacokinetics, pharmacology, therapeutic use)
  • Biological Availability
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Dermatitis (drug therapy)
  • Drug Industry
  • Drugs, Investigational (pharmacokinetics, pharmacology, therapeutic use)
  • Glycopeptides (pharmacokinetics, pharmacology, therapeutic use)
  • Gram-Positive Bacterial Infections (drug therapy)
  • Humans
  • Microbial Sensitivity Tests
  • Structure-Activity Relationship
  • Teicoplanin (analogs & derivatives)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: